BMO Capital Markets Analysts Give Merck & Co., Inc. (MRK) a $68.00 Price Target

Merck & Co., Inc. (NYSE:MRK) has been given a $68.00 target price by equities researchers at BMO Capital Markets in a report released on Wednesday. The firm presently has a “buy” rating on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 21.41% from the company’s previous close.

Several other equities analysts also recently weighed in on the stock. Jefferies Group reaffirmed a “sell” rating and set a $52.00 price target on shares of Merck & Co., Inc. in a report on Sunday, August 20th. Credit Suisse Group lowered their price target on shares of Merck & Co., Inc. from $75.00 to $74.00 and set an “outperform” rating on the stock in a report on Wednesday, August 30th. Sanford C. Bernstein reiterated a “buy” rating and set a $64.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, November 15th. SunTrust Banks cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Deutsche Bank reduced their price objective on shares of Merck & Co., Inc. from $62.00 to $59.00 and set a “hold” rating on the stock in a research report on Friday, November 24th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. Merck & Co., Inc. currently has a consensus rating of “Hold” and an average price target of $66.29.

Shares of Merck & Co., Inc. (NYSE MRK) traded down $0.42 during trading hours on Wednesday, reaching $56.01. 10,048,156 shares of the company’s stock traded hands, compared to its average volume of 9,761,317. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Co., Inc. has a twelve month low of $53.63 and a twelve month high of $66.80. The stock has a market capitalization of $155,483.63, a P/E ratio of 14.67, a P/E/G ratio of 2.64 and a beta of 0.76.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.08. Merck & Co., Inc. had a net margin of 11.60% and a return on equity of 27.08%. The business had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. research analysts expect that Merck & Co., Inc. will post 3.95 EPS for the current year.

Merck & Co., Inc. announced that its Board of Directors has authorized a stock repurchase program on Tuesday, November 28th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

In related news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.25% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Stelac Advisory Services LLC bought a new stake in Merck & Co., Inc. in the second quarter worth $104,000. Perennial Advisors LLC increased its position in Merck & Co., Inc. by 10.7% during the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after acquiring an additional 157 shares during the last quarter. Cascade Investment Advisors Inc. increased its position in Merck & Co., Inc. by 15.5% during the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the last quarter. Solaris Asset Management LLC increased its position in Merck & Co., Inc. by 6.3% during the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares during the last quarter. Finally, Harbour Capital Advisors LLC bought a new position in Merck & Co., Inc. during the first quarter valued at $127,000. Institutional investors own 73.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/14/bmo-capital-markets-analysts-give-merck-co-inc-mrk-a-68-00-price-target.html.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Leave a Reply